Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $1.8 million.

  • Whitehawk Therapeutics' Non Operating Income rose 10761.25% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.8 million, marking a year-over-year increase of 194682.54%. This contributed to the annual value of $3.8 million for FY2024, which is 3892.67% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Non Operating Income of $1.8 million as of Q3 2025, which was up 10761.25% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Non Operating Income peaked at $88.2 million during Q1 2025, and registered a low of -$1.4 million during Q1 2021.
  • Moreover, its 5-year median value for Non Operating Income was $1.2 million (2024), whereas its average is $5.5 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Non Operating Income surged by 1153576.72% in 2021, and later plummeted by 9572.83% in 2022.
  • Whitehawk Therapeutics' Non Operating Income (Quarter) stood at -$45000.0 in 2021, then surged by 3544.44% to $1.5 million in 2022, then fell by 6.77% to $1.4 million in 2023, then plummeted by 53.22% to $676000.0 in 2024, then skyrocketed by 166.27% to $1.8 million in 2025.
  • Its Non Operating Income stands at $1.8 million for Q3 2025, versus $2.1 million for Q2 2025 and $88.2 million for Q1 2025.